Blog
RSS FeedPosted by Michael Wonder on 02 May 2016
France gets G7 to discuss global regulation of medicine prices
2 May 2016 - France will press its G7 partners this month to launch an "irreversible" process to control the prices ...
Posted by Michael Wonder on 13 Apr 2016
Agenda for the 20 April 2016 TC meeting
13 April 2016 - The Transparency Commission will consider the reimbursement of Wakix (pitolisant), Busilvex (busulphan), Cosentyx (secukinumab), Anoro Ellipta (vilanterol ...
Posted by Michael Wonder on 12 Apr 2016
Agenda for the 13 April 2016 TC meeting
12 April 2016 - The Transparency Commission will consider the reimbursement of Praxbind (idarucizumab) and Xalatan (latanoprost). The Commission will also ...
Posted by Michael Wonder on 31 Mar 2016
Agenda for the 6 April 2016 TC meeting
31 March 2016 - The Transparency Commission will consider the reimbursement of pertuzumab (Perjeta), lixisenatide (Lyxumia), ezetimibe (Ezetrol) and secukinumab (Cosentyx). ...
Posted by Michael Wonder on 23 Mar 2016
France to call for lower drug prices at G7
22 March 2016 - France will announce a campaign to lower the price of new medicines, hoping world powers at the ...
Posted by Michael Wonder on 09 Mar 2016
Agenda for the 16 March 2016 TC meeting
9 March 2016 - The Transparency Commission will consider the reimbursement of ceftolozane sulphate with tazobactam sodium (Zerbaxa), lumacaftor with ivacaftor ...
Posted by Michael Wonder on 29 Feb 2016
Agenda for the 2 March 2016 TC meeting
1 March 2016 - The Transparency Commission will consider the reimbursement of daclatasvir dihydrochloride (Daklinza), ustekinumab (Stelara), radium Ra 223 dichloride ...
Posted by Michael Wonder on 11 Feb 2016
Agenda for the 17 February 2016 TC meeting
11 February 2016 - The Transparency Commission will consider the reimbursement of sonidegib diphosphate (Odomzo), emtricitabine with elvitegravir and cobicistat and ...
Posted by Michael Wonder on 29 Jan 2016
Agenda for the 3 February 2016 TC meeting
29 January 2016 - The Transparency Commission will consider the reimbursement of sufentanil (Zalviso), efmoroctocog alfa (Elocto) and asfotase alfa (Stensiq). ...
Posted by Michael Wonder on 18 Jan 2016
Agenda for the 20 January 2016 TC meeting
18 January 2016 - The Transparency Commission will consider the reimbursement of dronedarone hydrochloride (Multaq), palonosetron hydrochloride (AloxI), lanreotide acetate ...
Posted by Michael Wonder on 30 Dec 2015
Agenda for the 6 January 2016 TC meeting
31 December 2015 - The Transparency Commission will consider the reimbursement of adalimumab (Humira), delamanid (Deltyba), panobinostat lactate (Farydak), lenalidomide (Revlimid) ...
Posted by Michael Wonder on 10 Dec 2015
Agenda for the 16 December 2015 TC meeting
9 December 2015 - The Transparency Commission will consider the reimbursement of alirocumab (Praluent) for patients with hypercholesterolaemia and a new ...
Posted by Michael Wonder on 27 Nov 2015
Agenda for the 2 December 2015 TC meeting
27 November 2015 - The Transparency Commission will consider the reimbursement of nivolumab (Opdivo) for patients with non small cell ...
Posted by Michael Wonder on 18 Nov 2015
Agenda for the 18 November 2015 TC meeting
17 November 2015 - The Transparency Commission wiill consider submission for the following medicines: Jinarc (tolvaptan), Otezla (apremilast), Menotrophine (human ...
Posted by Michael Wonder on 30 Oct 2015
Agenda for the 4 November 2015 TC meeting
30 October 2015 - The TC will have its first look at Repatha (evolocumab) at the upcoming November 4 meeting. ...